Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6839921 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Acute myeloid leukemia patients | EXPERIMENTAL | - |
| Cohort 0 | EXPERIMENTAL | - |
| Solid tumor patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO6839921 | DRUG | Non-escalating IV doses given on Days 1-5 of Cycle 1. |
Inclusion Criteria: Cohort 0 and Arm A * Patient must have histologically or cytologically confirmed advanced cancer for which standard cures or relieving measures either do not exist, are ineffective or are not acceptable to the patient. * Measureable disease according to RECIST criteria version ...
RO6839921 is an investigational small molecule being studied for the treatment of advanced cancers, including acute myeloid leukemia. It is being developed by Roche Holding AG and is currently in Phase 1 clinical development.
RO6839921 targets MDM2, a protein that regulates the tumor suppressor p53. By antagonizing MDM2, the drug aims to restore p53 activity, which may help suppress tumor growth in cancers such as acute myeloid leukemia.
RO6839921 is being developed by Roche Holding AG, a biopharmaceutical company. The company is conducting clinical research on this investigational drug for oncology indications.
RO6839921 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and pharmacokinetics in patients.
RO6839921 has been studied in a Phase 1 clinical trial with the identifier NCT02098967. This completed trial evaluated the safety and pharmacokinetics of the drug in patients with advanced cancers, including acute myeloid leukemia, and enrolled 68 participants in the United States and Canada.
RO6839921 is an MDM2 antagonist, meaning it is a type of drug that inhibits MDM2. It is not the same as a generic MDM2 antagonist; rather, it is a specific investigational compound being developed by Roche Holding AG.